Literature DB >> 15640652

Afelimomab-another therapeutic option in sepsis therapy?

Guido Grass, Edmund Alwin Martin Neugebauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15640652     DOI： 10.1097/01.ccm.0000146134.86536.2f

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  2 in total

1.  Early report: The use of Cytosorb™ haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations.

Authors:  Craig Morris; Lewis Gray; Marco Giovannelli
Journal:  J Intensive Care Soc       Date:  2015-03-18

2.  Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.

Authors:  Eliseo Rondon; Ramesh Venkataraman
Journal:  Crit Care       Date:  2005-08-05       Impact factor: 9.097
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.